Endpoint	Endpoint reported in publication	Endpoint not reported in publication	Time of measurementa
Hero 2005	Review's primary outcomes
	Height measures	x	‐	12, 24 months
	Health‐related quality of life	‐	x	N/A
	Adverse events	x	‐	24 months
	Review's secondary outcomes
	All‐cause mortality	‐	x	N/A
	Cognitive outcomes	x	‐	12, 24 months
	Bone density	x	‐	6, 12, 18, 24 months
	Testosterone levels	x	‐	6,12,18, 24 months
	Lipid abnormalities	x	‐	12, 24 months
	Socioeconomic costs	‐	x	N/A
	Other than review's primary/secondary outcomes reported in publication (classification: P/S/O)b
	Body composition (S), insulin sensitivity (S), pubertal progression (S), vertebral morphology (S)
	Subgroups reported in publication
	Pubertal, prepubertal
Mauras 2008	Endpoint	Endpoint reported in publication	Endpoint not reported in publication	Time of measurementa
	Review's primary outcomes
	Height measures	x	‐	12, 24, 36 months
	Health‐related quality of life	‐	x	N/A
	Adverse events	x	‐	36 months
	Review's secondary outcomes
	All‐cause mortality	‐	x	N/A
	Cognitive outcomes	‐	x	N/A
	Bone density	x	‐	24, 36 months
	Testosterone levels	x	‐	6, 12, 18, 24, 30, 36 months
	Lipid abnormalities	x	‐	6, 12, 18, 24, 30, 36 months
	Socioeconomic costs	‐	x	N/A
	Other than review's primary/secondary outcomes reported in publication (classification: P/S/O)b
	Body composition (S)
	Subgroups reported in publication
	‐
Salehpour 2010	Endpoint	Endpoint reported in publication	Endpoint not reported in publication	Time of measurementa
	Review's primary outcomes
	Height measures	x	‐	24 months
	Health‐related quality of life	‐	x	N/A
	Adverse events	x	‐	24 months
	Review's secondary outcomes
	All‐cause mortality	‐	x	N/A
	Cognitive outcomes	‐	x	N/A
	Bone density	x	‐	24 months
	Testosterone levels	x	‐	12, 24 months
	Lipid abnormalities	x	‐	6, 12, 18, 24 months
	Socioeconomic costs	‐	x	N/A
	Other than review's primary/secondary outcomes reported in publication (classification: P/S/O)b
	Pubertal progression (S)
	Subgroups reported in publication
	‐
Wickman 2001	Endpoint	Endpoint reported in publication	Endpoint not reported in publication	Time of measurementa
	Review's primary outcomes
	Height measures	x	‐	2, 5, 12, 18 months
	Health‐related quality of life	‐	x	N/A
	Adverse events	‐	x	N/A
	Review's secondary outcomes
	All‐cause mortality	‐	x	N/A
	Cognitive outcomes	‐	x	N/A
	Bone density	x	‐	12, 18 months
	Testosterone levels	x	‐	2, 5, 12, 18 months
	Lipid abnormalities	x	‐	2, 5, 12, 18 months
	Socioeconomic costs	‐	x	N/A
	Other than review's primary/secondary outcomes reported in publication (classification: P/S/O)b
	Pubertal progression, gonadotropins, IGF‐1 and IGFBP3
	Subgroups reported in publication
	‐
"‐" denotes not reported aUnderlined data denote times of measurement for primary and secondary review outcomes, if measured and reported in the results section of the publication (other times represent planned but not reported points in time) b(P) Primary or (S) secondary endpoint(s) refer to verbatim statements in the publication, (O) other endpoints relate to outcomes that were not specified as 'primary' or 'secondary' outcomes in the publication IGF‐1: insulin‐like growth factor‐1; IGFBP3: insulin‐like growth factor binding protein 3; N/A: not applicable